Paul B. Yu
Chairman of Scientific Advisory BoardDr. Paul B. Yu, M.D., Ph.D. serves as Chairman of Scientific Advisory Board at IRulya Therapeutics Inc. (formerly known as Quince Therapeutics, Inc.) since June 2026. He served as Member of Scientific Advisory Board at Inozyme Pharma, Inc. since April 1, 2021until July 01, 2025. Dr. Yu is Scientific Advisory Board Member of INGENIA Therapeutics Inc. Dr. Yu serves as Member of Scientific Advisory Board at Keros Therapeutics, Inc. Dr. Yu is Associate Professor of Medicine at Harvard Medical School and Physician in Cardiovascular Medicine at Brigham and Women’s Hospital. Dr. Yu completed his A.B. in Philosophy and a B.S. in Biological Sciences at Stanford University, M.D. and Ph.D. (Immunology) degrees at Duke University. He completed residency in Internal Medicine at the University of California at San Francisco, clinical and research fellowships in Cardiovascular Disease at Massachusetts General Hospital and is board certified in Cardiovascular Medicine. Dr. Yu’s laboratory studies the function of bone morphogenetic protein (BMP) signaling in development and in vascular and musculoskeletal disease. The main focus of his laboratory’s work is to discern how BMP/TGF-ß signaling achieves spatio-temporal and functional specificity and modulates the tissue-specific consequences of inflammation and injury.
Positions
- Company NameIRulya Therapeutics Inc.Stock CodeIRLAPositionChairman of Scientific Advisory BoardColleagues
- BRBrigette RobertsCEO, Principal Executive Officer & Director
- JCJohn C. MilitelloCFO, Principal Financial Officer & Principal Accounting Officer
- KRKeith R. FandrickChief Operating Officer
- GRGuenter R. JanhoferChief Scientific Officer
- LDLeone D. PattersonDirector
- JPJames P. ValentineDirector
- MBMark BrodyMember of Clinical Advisory Board
